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ABSTRACT
Purpose. Talimogene laherparepvec (T-VEC) is an onco-
lytic immunotherapy designed to induce tumor regression
of injected lesions through direct lytic effects, and of
uninjected lesions through induction of systemic antitumor
immunity. In this study, we describe the patterns and time
course of response to T-VEC from the phase III OPTiM trial
of 436 patients with unresected stages IIIB–IV melanoma.
Methods. Lesion-level response analyses were performed
based on the type of lesion (injected or uninjected cuta-
neous, subcutaneous, or nodal lesions; or visceral lesions
[uninjected]), and the best percentage change from baseline
of the sum of products of the longest diameters was cal-
culated. Patients randomized to T-VEC (n = 295) who
experienced a durable response (continuous partial or
complete response for C6 months) were evaluated for
progression prior to response (PPR), defined as the
appearance of a new lesion or [25 % increase in total
baseline tumor area.
Results. T-VEC resulted in a decrease in size by C50 % in
64 % of injected lesions (N = 2116), 34 % of uninjected
non-visceral lesions (N = 981), and 15 % of visceral
lesions (N = 177). Complete resolution of lesions occurred
in 47 % of injected lesions, 22 % of uninjected non-vis-
ceral lesions, and 9 % of visceral lesions. Of 48 patients
with durable responses, 23 (48 %) experienced PPR,
including 14 who developed new lesions only. No differ-
ence in overall survival was observed, and median duration
of response was not reached in patients with PPR versus
those without PPR.
Conclusions. Responses in uninjected lesions provide
validation of T-VEC-induced systemic immunotherapeutic
effects against melanoma. PPR did not negatively impact
the clinical effectiveness of T-VEC.
Immunotherapies have proven to be powerful and
effective treatments for patients with advanced melanoma.
Talimogene laherparepvec (T-VEC) is a herpes simplex
virus (HSV) type 1-based oncolytic immunotherapy
designed to replicate selectively in tumors and produce
human granulocyte–macrophage colony-stimulating factor
(GM-CSF).1,2 In the randomized phase III OPTiM trial of
patients with unresectable stage IIIB–IV melanoma,
intralesional T-VEC administration yielded an improve-
ment in the primary endpoint of durable response rate
(DRR; defined as a response beginning in the first
12 months of treatment and lasting at least 6 months con-
tinuously) versus subcutaneous administration of GM-CSF
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(16 vs. 2 %; odds ratio 8.9; p\ 0.0001).3 Overall response
rate (ORR) was 26 % [11 % complete response (CR)] in
patients treated with T-VEC, and 6 % (1 % CR) in patients
treated with GM-CSF. Median overall survival (OS; a
secondary endpoint) in the T-VEC arm was 23.3 versus
18.9 months in the GM-CSF arm (hazard ratio [HR] 0.79,
95 % confidence interval [CI] 0.62–1.00; p = 0.051).3
T-VEC may induce tumor regression both through direct
lytic effects following intratumoral injection into tumors
and through secondary induction of systemic antitumoral
immunity in the context of virally mediated GM-CSF
production.1,4 The direct lytic effects are expected to
mediate rapid tumor responses in injected lesions. Induc-
tion of systemic immunity may require more time to prime
antigen-specific T cell responses, but could lead to
regression of uninjected tumors harboring shared tumor-
derived antigens with injected lesions. Similar dynamics of
antitumor response have been proposed for other
immunotherapeutic agents, such as with PD-1 pathway
inhibitors5–7 and anti-CTLA-4 inhibitors,6,7 with some
patients experiencing tumor progression prior to eventual
regression. Thus, the onset of immune-mediated tumor
responses may be delayed compared with the immediate
effects of cytotoxic agents and tyrosine kinase inhibitors.
Since responses to T-VEC in uninjected sites were
documented in some patients with melanoma in phase I and
II studies,2,4 we sought to validate, quantify, and charac-
terize the systemic effects of T-VEC in patients in OPTiM.
We compared response patterns of injected and uninjected
tumors in T-VEC-treated patients and conducted an anal-
ysis of overall responses to assess whether T-VEC, as with
other immunotherapies, induces delayed antitumor
responses.
MATERIALS AND METHODS
OPTiM Trial Design and Treatment
In this open-label, multicenter, phase III study, 436
patients with previously treated and untreated, unresected,
stage IIIB–IV melanoma were randomized 2:1 to receive
intralesional T-VEC or subcutaneous GM-CSF. The pri-
mary endpoint of OPTiM was DRR; key secondary
endpoints included ORR, OS, and safety. The clinical trial
design, treatment, and primary results have been reported.3
All participating sites had approval from the Institutional
Review Boards or Ethics Committees, and all participants
provided written, informed consent.
A treatment cycle of T-VEC consisted of two consecu-
tive injections (5 weeks for the first cycle and 4 weeks for
subsequent cycles). At each treatment session, injecting
new lesions followed by larger lesions was prioritized.
Visceral lesions were not allowed to be injected. Treatment
continued for at least 6 months, during which treatment
discontinuation for disease progression was not required;
an increase in lesion size or appearance of new lesions was
expected to occur in some patients based on the results
from a phase II study.2 After 6 months, treatment contin-
ued until clinically significant disease progression was
documented in association with a decline in performance
status, intolerability, or lack of injectable lesions.
Assessments
Visible or palpable lesions were evaluated by clinical
evaluation (caliper or ruler) at baseline and day 1 of each
treatment cycle. Deeper subcutaneous, nodal, or visceral
lesions were assessed by computed tomography (CT),
positron emission tomography/CT, and ultrasonography, if
appropriate, and performed at baseline and every
12 weeks. Overall tumor response was determined by
WHO criteria8 modified to allow patients who developed
new lesions or increase in lesion size to be evaluated for
tumor response later.3 In the event of response, any
residual cutaneous pigmented areas or other residual mas-
ses had to be documented as not containing tumor by a
representative biopsy. In addition, investigators were
encouraged to take biopsies of residual pigmented areas or
masses suspected of no longer containing the tumor at any
time point during the study. A blinded independent End-
point Assessment Committee (EAC) evaluated patients
with a best response per investigator of CR or PR, or who
received treatment for C9 months, by reviewing pho-
tographs of all visible lesions, other imaging assessments,
and biopsy results. Investigator measurements of individual
lesions and assessments of response were also collected
and analyzed for this report.
Lesion-Level Response Analysis
Since EAC-derived measurements were only available
for responders per investigator or those who had at a C9-
month treatment period, investigator-reported assessments
in 291 patients treated with T-VEC (four patients ran-
domized to T-VEC did not receive treatment) were used to
evaluate response of individual lesions during treatment.
The site, frequency, and location of injections were
recorded at the beginning of each treatment cycle.
For this analysis, lesions were considered evaluable for
response if two or more measurements were recorded at
two separate time points. Evaluations of individual lesion
responses were conducted using the best percentage change
from baseline with a cutoff of C50 % decrease in tumor
lesion size. This was defined as a product of the two largest
perpendicular diameters. Lesion-level response analyses
4170 R. H. I. Andtbacka et al.
were calculated based on the type of lesion: injected
(recorded as having been injected), uninjected non-visceral
(non-visceral lesions never recorded as having been
injected), and visceral (identified by medical review of
investigator-described locations of sites of the disease; per
protocol, injection of these lesions was not permitted).
Locations of visible or palpable tumor lesions were also
assigned to a body-site grid.
Progression Prior to Response Analysis
Patients randomized to the T-VEC arm who experi-
enced a DR were evaluated for PPR, defined as the
appearance of a new lesion or [25 % increase in base-
line total tumor area (the sum of the products of the two
largest perpendicular diameters of all index lesions at
baseline). Since all data for responders per investigators
were also assessed by an independent, treatment-blinded
EAC, EAC-reported measurements were used for the
PPR analysis. Responders by EAC were grouped as with
or without PPR. Responders with PPR were further
subdivided by progression in existing lesions (with or
without new lesions) or with appearance of new lesions
only. Responders without PPR were further divided by
durable response (DR) onset at B6 months from receiv-
ing initial T-VEC treatment, or DR onset after 6 months
from receiving initial T-VEC treatment.
RESULTS
Demographics and disease characteristics of T-VEC
treated patients in OPTiM are shown in electronic supple-
mentary Appendix 1. Among 295 patients randomized to the
T-VEC arm, four patients did not receive the allocated
treatment. The median number of lesions per T-VEC-treated
patient was 10 (range 1–58; Electronic Supplementary
Appendix 2), median number of lesions injected with T-VEC
per patient over the duration of the study was 5 (range 1–56;
Electronic Supplementary Appendix 2), and the mean vol-
ume of T-VEC administered per treatment was 2.8 mL
(interquartile range [IQR] 1.8–4.0).
Response of lesions to T-VEC
To separate local and systemic antitumor effects asso-
ciated with T-VEC treatment, analysis of changes in tumor
size as reported by investigators was conducted on 3274
evaluable baseline and new lesions from 285 evaluable
patients (6 of 291 patients who received T-VEC treatment
did not have two or more measurements for evaluating
tumor area change). Overall, 259 (91 %) of the 285
evaluable patients had three or more lesions.
Injected Lesions
A total of 2116 individual lesions injected with T-VEC
from 277 patients were evaluable per investigator assess-
ment. Of these, 1361 (64 %) lesions had a decrease in size
of C50 % (best percentage change from baseline),
including 995 (47 %) lesions that resolved completely
(Fig. 1a). Median time to response of responding injected
lesions from baseline was 9.3 weeks (IQR 5.1–17.1 weeks;
Electronic Supplementary Appendix 3). We next assessed
the relationship between regression in individual injected
lesions and overall patient responses (by modified WHO
criteria). Among 277 patients evaluable for response in
injected lesions, 37 % had C50 % decrease in total tumor
area of injected lesions and 16 % had complete resolution
of injected lesions. The ORR by investigator in these
patients was 32 %, with 15 % having a CR (Electronic
Supplementary Appendix 4).
Uninjected Non-visceral Lesions
Overall, 981 individual, uninjected, non-visceral lesions
(cutaneous, subcutaneous, or nodal) from 177 patients were
evaluable per investigator assessment. Of these, 331
(34 %) uninjected, non-visceral lesions decreased in size
by C50 %, and 212 (22 %) resolved completely (Fig. 1b).
Of 331 lesions that decreased in size by C50 %, 159
(48 %) were located in the same body site as injected
lesions and 77 (23 %) were located in a different body site
[95 (29 %) were not assigned body-site area; see Electronic
Supplementary Appendix 5 for additional details]. Median
time to response of responding uninjected non-visceral
lesions from baseline was 12.9 weeks (IQR 9.1–
20.9 weeks; Electronic Supplementary Appendix 3).
Among 177 patients evaluable for response in uninjected
non-visceral lesions, 21 % had C50 % decrease in total
tumor area of uninjected non-visceral lesions and 14 % had
complete resolution of uninjected non-visceral lesions,
which corresponded to an ORR of 18 % and a CR rate of
6 % (Electronic Supplementary Appendix 6).
Visceral Lesions
Overall, 177 individual visceral lesions from 79 patients
were evaluable per investigator assessment. Twenty-seven
(15 %) visceral lesions decreased in size by C50 %, and 16
(9 %) resolved completely (Fig. 1c). Evaluable visceral
lesions were located mainly in the lung (77 %), and also in
the liver (8 %), adrenal gland (6 %), spleen (3 %), kidney
(3 %), pancreas (1 %), and the thyroid, brain, and gas-
trointestinal tract (\1 % each). Among responding visceral
lesions, 81 % were in the lung, 15 % in the liver, and 4 %
in the thyroid. Median time to response of responding
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visceral lesions from baseline was 12.3 weeks (IQR 11.4–
36.9; Electronic Supplementary Appendix 3). Among 79
patients evaluable for response in visceral lesions, 10 %
had a C50 % decrease in total tumor area of visceral
lesions and 6 % had complete resolution of visceral
lesions. ORR was 14 % and the CR rate was 3 % (Elec-
tronic Supplementary Appendix 7).
PATTERNS OF RESPONSE IN T-VEC-TREATED
PATIENTS
In OPTiM, 295 were randomized to T-VEC and 141 to
GM-CSF (Fig. 2). In the GM-CSF arm, only three (2 %)
patients experienced a DR as per the EAC, therefore the
current analysis was limited to the T-VEC arm. Forty-eight
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FIG. 1 T-VEC administration generated response in both injected
and uninjected tumor lesions, including visceral lesions. Response of
a individual injected lesions; b uninjected non-visceral lesions; and c
visceral lesions (also uninjected). Vertical axis depicts maximal
change in individual tumor lesion size (products of the two largest
perpendicular diameters) from baseline
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patients (16 %) treated with T-VEC experienced a DR
(Fig. 2). Of these, 25 (52 %) did not have PPR and 23
(48 %) had PPR. Forty (83 %) of 48 T-VEC-treated
patients with a DR had responses ongoing at the time of
this analysis (range 10.8–19.2 months; median follow-up
18.4 months). Of these 40 patients with ongoing DR, 18
did not have PPR and 22 had PPR (p = 0.27).
In 48 T-VEC-treated patients with a DR, median time to
DR onset was 3.1 months (range 1.2–9.5 months) in
patients without PPR versus 5.8 months (range1.3–
10.6 months) in patients with a PPR (p = 0.004). Median
duration of DR was not reached in both groups, with a
minimum duration of response of 6.3 months for patients
with PPR and 6.2 months for patients without PRR (the
response with shortest duration was ongoing at time of this
analysis). In unadjusted comparison of durable responders
with PPR and those without PRR, no difference in OS was
observed (log rank p = 0.35, HR 0.35, 95 % CI 0.04–3.44;
Electronic Supplementary Appendix 8). Median OS was
not reached for either group at the time of this analysis.
Of 25 patients without PPR, 21 (84 %) had a DR that
began within the first 6 months of receiving T-VEC
(Fig. 2). Figure 3a depicts changes in tumor area from
baseline of these patients, and examples are shown in
Fig. 4a and Electronic Supplementary Appendix 9. Four
(16 %) patients without PPR had a DR that began after
6 months (Fig. 3b; see Fig. 4b for an example).
In 23 patients with PPR, 14 (61 %) experienced pro-
gression due to the appearance of a new lesion(s) prior to
DR onset (Fig. 3c; see Electronic Supplementary Appendix
10 for an example) and 9 (39 %) experienced PPR due to
an increase in the size of existing lesions with or without
the appearance of new lesion(s) (Fig. 3d; see Fig. 5 for an
example).
DISCUSSION
In this study, T-VEC administration yielded regression
of C50 % in 64 % of injected lesions (with approximately
half of the injected lesions resolving completely) and in
uninjected lesions (34 % in non-visceral and 15 % in vis-
ceral). Delayed tumor responses due to PPR occurred in
approximately half of the T-VEC-treated patients with
DRs. PPR did not appear to significantly impact the dura-
tion and quality of DRs or OS.
Local tumor lysis achieved by direct injection of T-VEC
into the lesion is believed to lead to release of tumor-
derived antigens, and virally encoded GM-CSF potentiates
systemic antitumor immune responses. Preclinical results
indicated that incorporation of GM-CSF into the oncolytic
virus was important for the systemic antitumor effect of T-
VEC since this resulted in increased tumor shrinkage of
uninjected tumors in mice.1 In a phase II study in patients
with melanoma,9 an ORR of 26 % was reported, with
responses frequently observed in uninjected lesions,
including visceral lesions. Supporting evidence of the
systemic effect of T-VEC came from biopsies that were
taken from injected and uninjected lesions in 11 of the 50
patients treated with T-VEC. Analysis of regressing
lesions, including uninjected lesions, suggested an associ-
ation between response and the presence of MART-1-
specific CD8? T cells and reduction in CD4? regulatory T
cells, consistent with induction of host antitumor
immunity.9
To further understand the systemic effects of T-VEC, we
performed an analysis of the response of individual lesions
from patients in the phase III OPTiM trial. Consistent with
previous observations,9 T-VEC administration resulted in
responses in both injected and uninjected lesions. These
FIG. 2 Analysis of the patterns
of response in T-VEC-treated
patients in OPTiM. * Includes
three patients with PPR in
existing lesions who may have
also developed new lesions.
PPR progression prior to
response, GM-CSF
granulocyte–macrophage
colony-stimulating factor, DR
durable response
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FIG. 3 Four distinct patterns of response in T-VEC-treated patients.
a Without PPR and DR onset B6 months; b without PPR and DR
onset [6 months; c with PPR due to new lesions only; and d with
PPR due to existing lesions (with or without new lesions). The
vertical axis depicts the change in tumor area from baseline, as
assessed by the Endpoint Assessment Committee. PPR progression
prior to response, DR durable response
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individual lesion responses occurred earlier in injected
lesions, likely due to the time required for a systemic
immune response to be established. The systemic effects of
T-VEC were unlikely due to direct exposure of uninjected
lesions to the oncolytic virus from adjacent injected
lesions, as responses were seen in visceral lesions and in
uninjected non-visceral lesions located in different body
sites than injected lesions.
Similar to other immunotherapies,10 some T-VEC-trea-
ted patients experienced PPR. Nearly half of all T-VEC
durable responders experienced PPR, with the majority of
these progression events being due to development of new
lesions. While DR occurred nearly 3 months earlier in
patients without PPR versus those with PPR, the percent-
age of patients with a DR ongoing at the time of this
analysis was similar in both groups. Thus, PPR did not
seem to adversely impact the duration of response.
Responses after an initial increase in tumor size or
appearance of new lesions have been observed in patients
with melanoma treated with immunotherapies such as
ipilimumab (10 % of treated patients who were initially
characterized with disease progression),10,11 nivolumab
(4 % of all treated patients),5,6 and pembrolizumab (9 % of
evaluable treated patients).7 In addition to melanoma, PPR
(pseudoprogression) was reported for other tumor types
treated with checkpoint inhibitors.12 Therefore, the occur-
rence of subsequent responses, including complete disease
resolution that occurs in some patients, may justify con-
tinued treatment with immunotherapies despite early
disease progression. Distinguishing true progression from
pseudoprogression is likely to be a challenge with T-VEC
and other immunotherapies that display delayed tumor
responses due to inflammatory tumor infiltrates.13,14
In this study, patients with PPR relative to those without
PPR had younger median age, better Eastern Cooperative
Oncology Group (ECOG) performance status, more HSV-1
seronegativity at baseline, more female patients, and more
patients who received T-VEC as C2 line of therapy.
However, due to the small numbers, as well as unknown
data for potential confounding characteristics (e.g. BRAF
status), formal comparisons were impractical. Research in
a larger cohort of patients as well as parallel efforts to find
biomarkers are needed to help identify patients who may
experience true progression versus pseudoprogression.
Conventional response criteria such as RECIST15 and
WHO8 that rely on tumor shrinkage subsequent to treat-
ment as an indicator of antitumor activity may
underestimate the full benefit of immunotherapies.12
Immune-related response criteria, in which new lesions are
incorporated into the total tumor area and disease pro-
gression criteria, and require confirmation of C25 %
increase in total tumor area C4 weeks later, have been
proposed to address distinct response patterns observed
with immunotherapies, specifically disease progression
followed by response.10 The data reported here and by
others5,6,10,11 provide additional support for the use of
revised response criteria in evaluating immunotherapies.
CONCLUSIONS
T-VEC demonstrates response in injected and unin-
jected lesions, and represents a new first-in-class oncolytic
virus immunotherapy for patients with melanoma. These
data also suggest that, similar to other novel immunother-
apies, more patients may have benefited from treatment
with T-VEC due to the delayed nature of tumor regression.
Opportunities to enhance T-VEC activity could include
Week 18Baseline
Baseline Week 26
Week 78Week 46
(a)
(b)
FIG. 4 Examples of patients treated with T-VEC with a DR without
PPR. a Patient without PPR and DR onset B6 months. The patient
had recurrent stage IIIC melanoma with multiple in-transit tumor
lesions on the leg. All lesions were injected with T-VEC and all
resolved (CR) by 37 weeks after the start of treatment. The patient
remained in CR until the end of the study, with DR duration of
60 weeks. b Patient without PPR and measurable response onset
[6 months. The patient had recurrent stage IIIB (in-transit)
melanoma of the scalp with 20 cutaneous lesions that were injected
with T-VEC. Partial response was recorded on week 30 after the start
of treatment. Lesions resolved completely by week 38 and the patient
remained in CR until the end of the study, with DR duration of
48 weeks. Responses are reported per External Assessment Commit-
tee. Titles above each photography are weeks on study. DR durable
response, PRR progression prior to response, CR complete response
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direct injection of visceral lesions and/or combination with
immune checkpoint inhibitors. Early reports from a phase
Ib clinical trial of T-VEC and ipilimumab suggest a
response rate of 56 % and a CR rate of 33 %; a randomized
phase II study is ongoing.16 Future studies will likely focus
on defining the specific mechanisms by which T-VEC
mediates tumor regression and the development of rational
combination therapies to improve the potential of this agent
for patients with cancer, in both melanoma and other
tumors.
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